Radica Z. Alicic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Radica Z. Alicic has a total of 131 co-authors. Here are the top co-authors by number of shared publications:
- Katherine R. Tuttle
Providence Inland Northwest Health, University of Washington School of Medicine, Spokane, WA
19 shared publications Joshua J. Neumiller
Providence Medical Research Center, Providence Inland Northwest Health, Spokane, WA, USA; Department of Pharmacotherapy, College of Pharmacy and Pharmaceutical Sciences, Washington State University, 412 E. Spokane Falls Boulevard, Spokane, WA 99210, USA
9 shared publications- Joshua J. Neumiller
College of Pharmacy and Pharmaceutical Sciences, Washington State University Spokane Washington USA
7 shared publications Katherine R. Tuttle
Providence Medical Research Center, Providence Health Care, Spokane, Washington, USA
4 shared publications- Susanne B. Nicholas
University of California, Los Angeles
4 shared publications Cami R. Jones
Providence Medical Research Center, Providence Inland Northwest Health, Spokane, Washington
3 shared publications
Latest Publications
- 4 September 2026
- Published by Springer Nature in Nature Reviews Nephrology
- Vol. 22 (11) , 784-802
Inflammation as a therapeutic target to improve kidney and cardiovascular outcomes
Chronic kidney disease (CKD) is a leading cause of premature death due to the loss of kidney function and development of kidney failure, and because of attendant major adverse cardiovascular events. High-sensitivity C-reactive protein (hsCRP), a biomarker of systemic inflammation, is associated with increased risks of cardiovascular events and CKD progression. CKD is characterized by a pro-inflammatory state with upregulation of inflammatory pathways and disruption of anti-inflammatory mechanisms. The resulting systemic inflammation, along with local tissue-based inflammatory mechanisms, are key contributors to kidney damage, atherosclerosis and cardiac dysfunction. As a result, a series of inflammatory pathways and mediators have emerged as potential therapeutic targets for CKD and its major cardiovascular complications. Investigational treatments that have targeted inflammation include inhibition of apoptosis signal-regulating kinase-1 (ASK1) by selonsertib, Janus kinase (JAK) 1/2 inhibition with baricitinib, protein kinase C-β (PKCβ) inhibition with ruboxistaurin, nuclear factor erythroid 2-related factor 2 (Nrf2) activation with bardoxolone, phosphodiesterase inhibition with pentoxifylline and monoclonal antibodies against IL-1β and IL-6. Furthermore, proven therapies for CKD, including renin–angiotensin–aldosterone system inhibitors, sodium–glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid antagonists, possess anti-inflammatory properties that might contribute to their previously established clinical benefits.
- 4 September 2026
- Published by Springer Nature in Nature Reviews Nephrology
- Vol. 22 (11) , 784-802
Inflammation as a therapeutic target to improve kidney and cardiovascular outcomes
Chronic kidney disease (CKD) is a leading cause of premature death due to the loss of kidney function and development of kidney failure, and because of attendant major adverse cardiovascular events. High-sensitivity C-reactive protein (hsCRP), a biomarker of systemic inflammation, is associated with increased risks of cardiovascular events and CKD progression. CKD is characterized by a pro-inflammatory state with upregulation of inflammatory pathways and disruption of anti-inflammatory mechanisms. The resulting systemic inflammation, along with local tissue-based inflammatory mechanisms, are key contributors to kidney damage, atherosclerosis and cardiac dysfunction. As a result, a series of inflammatory pathways and mediators have emerged as potential therapeutic targets for CKD and its major cardiovascular complications. Investigational treatments that have targeted inflammation include inhibition of apoptosis signal-regulating kinase-1 (ASK1) by selonsertib, Janus kinase (JAK) 1/2 inhibition with baricitinib, protein kinase C-β (PKCβ) inhibition with ruboxistaurin, nuclear factor erythroid 2-related factor 2 (Nrf2) activation with bardoxolone, phosphodiesterase inhibition with pentoxifylline and monoclonal antibodies against IL-1β and IL-6. Furthermore, proven therapies for CKD, including renin–angiotensin–aldosterone system inhibitors, sodium–glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid antagonists, possess anti-inflammatory properties that might contribute to their previously established clinical benefits.
- 23 June 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (9) , 1521-1530
Major Adverse Kidney Events in the American Indian or Alaska Native Population with Diabetes
Background: Chronic kidney disease (CKD) and diabetes disproportionately affect the American Indian or Alaska Native population but understanding of major adverse kidney events (MAKE) in this population is limited. Methods: Electronic health records from the Providence health system identified the American Indian or Alaska Native adult population with diabetes during 2013-2022. A one-year window surrounding diabetes cohort entry was used to collect baseline data. Kaplan-Meier analyses assessed MAKE (≥40% estimated glomerular filtration rate [eGFR] decline, eGFR 2 , dialysis or kidney transplant, and all-cause death) with propensity score matching (1:3) of American Indian or Alaska Native people to reference individuals (non-Hispanic White) by demographics and clinical characteristics. Cox proportional hazards modeling estimated associations between demographic, clinical, social, and healthcare utilization variables and MAKE. Results: The American Indian or Alaska Native population (N=6,103) was younger (mean±standard deviation age 54±15 years) with higher HbA1c (mean 7.4±2.2 mg/dL) compared to the reference population (N=354,283; age 62±14 years; HbA1c 6.9%±1.8%). During a median follow-up of 4.1 (interquartile range 2.0-6.4) years, the American Indian or Alaska Native population experienced a higher frequency of MAKE (26%, n=1,614) than the reference population (24%, n=85,920). With propensity score matching, MAKE survival estimates were significantly lower in the American Indian or Alaska Native population (p <0.0001). In the adjusted Cox model, increased MAKE risk was observed for the American Indian or Alaska Native population (versus reference population, hazard ratio [HR] 1.20, 95% confidence interval [CI] 1.15-1.27), higher social vulnerability index (HR 1.05, 95% CI 1.05-1.05), and hospitalization (HR 1.98, 95% CI 1.95-2.01), while more primary care visits were associated with lower MAKE risk (HR 0.78, 95% CI 0.77-0.79). Conclusion: The risk of MAKE was significantly increased in the American Indian or Alaska Native population with diabetes. Social factors and healthcare utilization importantly contributed to risk prediction for MAKE.
- 23 June 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (9) , 1521-1530
Major Adverse Kidney Events in the American Indian or Alaska Native Population with Diabetes
Background: Chronic kidney disease (CKD) and diabetes disproportionately affect the American Indian or Alaska Native population but understanding of major adverse kidney events (MAKE) in this population is limited. Methods: Electronic health records from the Providence health system identified the American Indian or Alaska Native adult population with diabetes during 2013-2022. A one-year window surrounding diabetes cohort entry was used to collect baseline data. Kaplan-Meier analyses assessed MAKE (≥40% estimated glomerular filtration rate [eGFR] decline, eGFR 2 , dialysis or kidney transplant, and all-cause death) with propensity score matching (1:3) of American Indian or Alaska Native people to reference individuals (non-Hispanic White) by demographics and clinical characteristics. Cox proportional hazards modeling estimated associations between demographic, clinical, social, and healthcare utilization variables and MAKE. Results: The American Indian or Alaska Native population (N=6,103) was younger (mean±standard deviation age 54±15 years) with higher HbA1c (mean 7.4±2.2 mg/dL) compared to the reference population (N=354,283; age 62±14 years; HbA1c 6.9%±1.8%). During a median follow-up of 4.1 (interquartile range 2.0-6.4) years, the American Indian or Alaska Native population experienced a higher frequency of MAKE (26%, n=1,614) than the reference population (24%, n=85,920). With propensity score matching, MAKE survival estimates were significantly lower in the American Indian or Alaska Native population (p <0.0001). In the adjusted Cox model, increased MAKE risk was observed for the American Indian or Alaska Native population (versus reference population, hazard ratio [HR] 1.20, 95% confidence interval [CI] 1.15-1.27), higher social vulnerability index (HR 1.05, 95% CI 1.05-1.05), and hospitalization (HR 1.98, 95% CI 1.95-2.01), while more primary care visits were associated with lower MAKE risk (HR 0.78, 95% CI 0.77-0.79). Conclusion: The risk of MAKE was significantly increased in the American Indian or Alaska Native population with diabetes. Social factors and healthcare utilization importantly contributed to risk prediction for MAKE.
- Top Cited Papers
- 8 January 2026
- Published by Springer Nature in Nature Reviews Nephrology
- Vol. 22 (4) , 265-282
GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease
Chronic kidney disease (CKD) remains a major public health problem, with type 2 diabetes and obesity representing key risk factors worldwide. The complex pathophysiology and the metabolic risk factors shared between type 2 diabetes, obesity, CKD and cardiovascular disease have led to the concept of a cardiovascular–kidney–metabolic (CKM) syndrome. The treatment landscape for CKM changed dramatically when agents from several medication classes, originally developed as glucose-lowering therapies, were recognized to reduce the risk of multiple components of CKM syndrome. Incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual glucose-dependent insulinotropic–GLP-1RAs, have evolved from metabolic therapies to agents with either proven or potential protective effects on the kidney and heart. In addition to their potent metabolic actions that reduce hyperglycaemia and body weight, GLP-1RAs also lower the risk of major kidney, cardiovascular and mortality outcomes across broad populations with cardiovascular disease or CKD, with and without diabetes or obesity. GLP-1RAs have been combined with glucose-dependent insulinotropic agonism, as well as glucagon agonism or amylin analogues to further enhance their metabolic benefits. However, kidney and heart protection are not fully explainable by the metabolic actions of these agents. Rather, a growing body of evidence suggests that the systemic and local actions of incretins and metabolic hormones modulate multiple pathways that can promote inflammatory and fibrotic injury.
- 8 January 2026
- Published by Springer Nature in Nature Reviews Nephrology
- Vol. 22 (4) , 265-282
Top Cited PapersGLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease
Chronic kidney disease (CKD) remains a major public health problem, with type 2 diabetes and obesity representing key risk factors worldwide. The complex pathophysiology and the metabolic risk factors shared between type 2 diabetes, obesity, CKD and cardiovascular disease have led to the concept of a cardiovascular–kidney–metabolic (CKM) syndrome. The treatment landscape for CKM changed dramatically when agents from several medication classes, originally developed as glucose-lowering therapies, were recognized to reduce the risk of multiple components of CKM syndrome. Incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual glucose-dependent insulinotropic–GLP-1RAs, have evolved from metabolic therapies to agents with either proven or potential protective effects on the kidney and heart. In addition to their potent metabolic actions that reduce hyperglycaemia and body weight, GLP-1RAs also lower the risk of major kidney, cardiovascular and mortality outcomes across broad populations with cardiovascular disease or CKD, with and without diabetes or obesity. GLP-1RAs have been combined with glucose-dependent insulinotropic agonism, as well as glucagon agonism or amylin analogues to further enhance their metabolic benefits. However, kidney and heart protection are not fully explainable by the metabolic actions of these agents. Rather, a growing body of evidence suggests that the systemic and local actions of incretins and metabolic hormones modulate multiple pathways that can promote inflammatory and fibrotic injury.
- 8 September 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (1) , 83-94
A Real-World Cohort Study of the Risks of Kidney Failure and Death in Diabetes
Key Points: Rates and risks of kidney failure versus death in diabetes have not been previously quantified across a full range of kidney function. In a large population with diabetes, risk of death exceeded kidney failure overall, but kidney failure outpaced death at eGFR 2 . Current risk estimates are needed to support public health and clinical strategies to monitor and improve kidney health in diabetes. Background: Risks of kidney failure versus death in diabetes have not been previously quantified across a full range of kidney function. The aim of the study was to assess competing risks of kidney failure and death in a real-world cohort with diabetes. Methods: Cumulative incidence (CMI) functions for kidney failure and death, stratified by baseline eGFR, were estimated for the diabetes population from electronic health record data at Providence and the University of California Los Angeles health systems. Cox proportional hazards models assessed predictors of kidney failure and death. For kidney failure, cause-specific hazards were modeled with competing risk of death. Results: Among 618,739 persons with diabetes followed for a median (interquartile range) of 3.79 (1.80–6.00) years during 2013–2022, 4% ( n =24,097) developed kidney failure and 10% ( n =63,128) died. Five-year CMI of kidney failure increased from 2% (95% confidence interval, 1.4% to 1.5%) for eGFR ≥90 ml/min per 1.73 m 2 to 62% (95% confidence interval, 61.0% to 63.5%) for eGFR 15–29 ml/min per 1.73 m 2 . CMI of all-cause death was higher than kidney failure with eGFR ≥45 ml/min per 1.73 m 2 , whereas kidney failure became more common at eGFR 2 . Hazards of kidney failure were higher in men (reference: women), 40–59 and 60–79-year groups (reference: 18–39 years), non-White race or Hispanic or Latino/a ethnicity groups (reference: non-Hispanic White), and by noncommercial (reference: commercial) health insurance or hospitalization (yes/no) within 1 year before follow-up. Hazards of death were similar except that age ≥80 years imparted the highest risk, and only the American Indian or Alaska Native and other race groups had higher risk. Conclusions: Death was more likely than kidney failure at eGFR ≥45 ml/min per 1.73 m 2 , but this trend reversed at eGFR 2 . These contemporary risk estimates are important for public health and clinical strategies for monitoring and interventions to improve kidney health in diabetes.
- 8 September 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (1) , 83-94
A Real-World Cohort Study of the Risks of Kidney Failure and Death in Diabetes
Key Points: Rates and risks of kidney failure versus death in diabetes have not been previously quantified across a full range of kidney function. In a large population with diabetes, risk of death exceeded kidney failure overall, but kidney failure outpaced death at eGFR 2 . Current risk estimates are needed to support public health and clinical strategies to monitor and improve kidney health in diabetes. Background: Risks of kidney failure versus death in diabetes have not been previously quantified across a full range of kidney function. The aim of the study was to assess competing risks of kidney failure and death in a real-world cohort with diabetes. Methods: Cumulative incidence (CMI) functions for kidney failure and death, stratified by baseline eGFR, were estimated for the diabetes population from electronic health record data at Providence and the University of California Los Angeles health systems. Cox proportional hazards models assessed predictors of kidney failure and death. For kidney failure, cause-specific hazards were modeled with competing risk of death. Results: Among 618,739 persons with diabetes followed for a median (interquartile range) of 3.79 (1.80–6.00) years during 2013–2022, 4% ( n =24,097) developed kidney failure and 10% ( n =63,128) died. Five-year CMI of kidney failure increased from 2% (95% confidence interval, 1.4% to 1.5%) for eGFR ≥90 ml/min per 1.73 m 2 to 62% (95% confidence interval, 61.0% to 63.5%) for eGFR 15–29 ml/min per 1.73 m 2 . CMI of all-cause death was higher than kidney failure with eGFR ≥45 ml/min per 1.73 m 2 , whereas kidney failure became more common at eGFR 2 . Hazards of kidney failure were higher in men (reference: women), 40–59 and 60–79-year groups (reference: 18–39 years), non-White race or Hispanic or Latino/a ethnicity groups (reference: non-Hispanic White), and by noncommercial (reference: commercial) health insurance or hospitalization (yes/no) within 1 year before follow-up. Hazards of death were similar except that age ≥80 years imparted the highest risk, and only the American Indian or Alaska Native and other race groups had higher risk. Conclusions: Death was more likely than kidney failure at eGFR ≥45 ml/min per 1.73 m 2 , but this trend reversed at eGFR 2 . These contemporary risk estimates are important for public health and clinical strategies for monitoring and interventions to improve kidney health in diabetes.
- 29 July 2025
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 178 (9) , 1287-1297
Social Determinants of Health and Risk for Long COVID in the U.S. RECOVER-Adult Cohort
Social determinants of health (SDoH) contribute to disparities in SARS-CoV-2 infection, but their associations with long COVID are unknown. To determine associations between SDoH at the time of SARS-CoV-2 infection and risk for long COVID. Prospective observational cohort study. 33 states plus Washington, DC, and Puerto Rico. Adults (aged ≥18 years) enrolled in RECOVER-Adult (Researching COVID to Enhance Recovery) between October 2021 and November 2023 who were within 30 days of SARS-CoV-2 infection; completed baseline SDoH, comorbidity, and pregnancy questionnaires; and were followed prospectively. Social risk factors from SDoH baseline questionnaires, ZIP code poverty and household crowding measures, and a weighted score of 11 or higher on the Long COVID Research Index 6 months after infection. Among 3787 participants, 418 (11%) developed long COVID. After adjustment for demographic characteristics, pregnancy, disability, comorbidities, SARS-CoV-2 severity, and vaccinations, financial hardship (adjusted marginal risk ratio [ARR], 2.36 [95% CI, 1.97 to 2.91]), food insecurity (ARR, 2.36 [CI, 1.83 to 2.98]), less than a college education (ARR, 1.60 [CI, 1.30 to 1.97]), experiences of medical discrimination (ARR, 2.37 [CI, 1.94 to 2.83]), skipped medical care due to cost (ARR, 2.87 [CI, 2.22 to 3.70]), and lack of social support (ARR, 1.79 [CI, 1.50 to 2.17]) were associated with increased risk for long COVID. Living in ZIP codes with the highest (vs. lowest) household crowding was also associated with greater risk (ARR, 1.36 [CI, 1.05 to 1.71]). Selection bias may influence observed associations and generalizability. Participants with social risk factors at the time of SARS-CoV-2 infection had greater risk for subsequent long COVID than those without. Future studies should determine whether social risk factor interventions mitigate long-term effects of SARS-CoV-2 infection. National Institutes of Health.
- 29 July 2025
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 178 (9) , 1287-1297
Social Determinants of Health and Risk for Long COVID in the U.S. RECOVER-Adult Cohort
Social determinants of health (SDoH) contribute to disparities in SARS-CoV-2 infection, but their associations with long COVID are unknown. To determine associations between SDoH at the time of SARS-CoV-2 infection and risk for long COVID. Prospective observational cohort study. 33 states plus Washington, DC, and Puerto Rico. Adults (aged ≥18 years) enrolled in RECOVER-Adult (Researching COVID to Enhance Recovery) between October 2021 and November 2023 who were within 30 days of SARS-CoV-2 infection; completed baseline SDoH, comorbidity, and pregnancy questionnaires; and were followed prospectively. Social risk factors from SDoH baseline questionnaires, ZIP code poverty and household crowding measures, and a weighted score of 11 or higher on the Long COVID Research Index 6 months after infection. Among 3787 participants, 418 (11%) developed long COVID. After adjustment for demographic characteristics, pregnancy, disability, comorbidities, SARS-CoV-2 severity, and vaccinations, financial hardship (adjusted marginal risk ratio [ARR], 2.36 [95% CI, 1.97 to 2.91]), food insecurity (ARR, 2.36 [CI, 1.83 to 2.98]), less than a college education (ARR, 1.60 [CI, 1.30 to 1.97]), experiences of medical discrimination (ARR, 2.37 [CI, 1.94 to 2.83]), skipped medical care due to cost (ARR, 2.87 [CI, 2.22 to 3.70]), and lack of social support (ARR, 1.79 [CI, 1.50 to 2.17]) were associated with increased risk for long COVID. Living in ZIP codes with the highest (vs. lowest) household crowding was also associated with greater risk (ARR, 1.36 [CI, 1.05 to 1.71]). Selection bias may influence observed associations and generalizability. Participants with social risk factors at the time of SARS-CoV-2 infection had greater risk for subsequent long COVID than those without. Future studies should determine whether social risk factor interventions mitigate long-term effects of SARS-CoV-2 infection. National Institutes of Health.
- 2 April 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (6) , 3536-3541
Incidence of chronic kidney disease among adults with prediabetes in the CURE ‐ CKD registry, 2013–2020
- 2 April 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (6) , 3536-3541
Incidence of chronic kidney disease among adults with prediabetes in the CURE ‐ CKD registry, 2013–2020
- Top Cited PapersOpen Access
- 1 January 2025
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 40 (Supplement) , i3-i17
Combination therapy: an upcoming paradigm to improve kidney and cardiovascular outcomes in chronic kidney disease
PLAIN ENGLISH SUMMARY: : In this article the authors review recent advances in the treatment of chronic kidney disease (CKD) with diabetes, and summarize evidence supporting combination therapy approaches to improve patient outcomes. Driven by the global rise in diabetes, the worldwide burden of CKD has nearly doubled since the 1990s. People with CKD have notably increased risks for premature cardiovascular disease (heart and blood vessels disease), kidney failure and death. CKD, diabetes, obesity and cardiovascular disease are closely interrelated and share common risk factors. These health conditions therefore comprise what is now known as cardiovascular–kidney–metabolic (CKM) syndrome. Recently approved medications, including sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and the non-steroidal mineralocorticoid receptor antagonist (ns-MRA) finerenone, represent agents capable of reducing metabolic, kidney and cardiovascular risk through complementary mechanisms of action. Current evidence supports use of these therapies in combination. Besides providing additive protective effects, combination therapy may also help reduce side effects. For instance, using an SGLT2 inhibitor in combination with finerenone helps decrease the risk for high potassium levels. Through the multipronged approach, combination therapy allows tailoring treatment for the individual patient characteristics and needs. Several planned and ongoing clinical trials continue to study the benefits of combination therapy in people with CKM syndrome. With building evidence supporting the use of combination therapy, it is crucial to raise awareness of the importance of this treatment approach and develop processes to incorporate new therapies into every day practice to support optimal care and improved outcomes. The global burden of chronic kidney disease (CKD) increased by nearly 90% in the period spanning 1990 to 2016, mostly attributed to an increase in the prevalence of CKD in diabetes. People living with CKD have an elevated lifetime risk for cardiovascular disease (CVD) when compared with the general population, with risk increasing in parallel with albuminuria and kidney function decline. Metabolic disease, CKD and CVD share common risk factors including neurohumoral activation, systemic inflammation and oxidative stress, thus prompting the introduction of a broader construct of cardiovascular–kidney–metabolic (CKM) syndrome. An important rationale for the introduction of this concept are recent and ongoing therapeutic advancements fundamentally changing CKM management. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and the non-steroidal mineralocorticoid receptor antagonist (ns-MRA) finerenone have shifted the therapeutic paradigm for patients with CKD and have emerged in rapid succession as cornerstones of guideline-directed medical therapy (GDMT). Recently completed clinical trials of aldosterone synthase inhibitors and endothelin receptor antagonists have additionally reported additive antiproteinuric effects on the background of renin–angiotensin system and SGLT2 inhibition, with acceptable safety profiles. The sum of current evidence from both preclinical and clinical studies support combination therapy in the setting of CKD to achieve additive and potentially synergistic kidney and heart protection by addressing metabolic, hemodynamic, and pro-inflammatory and pro-fibrotic mechanistic pathways. This narrative review will discuss available evidence supporting combination GDMT in CKD with diabetes and additionally discuss ongoing and future trials evaluating the efficacy and safety of combination therapies for CKD with or without diabetes.
- 1 January 2025
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 40 (Supplement) , i3-i17
Top Cited PapersOpen AccessCombination therapy: an upcoming paradigm to improve kidney and cardiovascular outcomes in chronic kidney disease
PLAIN ENGLISH SUMMARY: : In this article the authors review recent advances in the treatment of chronic kidney disease (CKD) with diabetes, and summarize evidence supporting combination therapy approaches to improve patient outcomes. Driven by the global rise in diabetes, the worldwide burden of CKD has nearly doubled since the 1990s. People with CKD have notably increased risks for premature cardiovascular disease (heart and blood vessels disease), kidney failure and death. CKD, diabetes, obesity and cardiovascular disease are closely interrelated and share common risk factors. These health conditions therefore comprise what is now known as cardiovascular–kidney–metabolic (CKM) syndrome. Recently approved medications, including sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and the non-steroidal mineralocorticoid receptor antagonist (ns-MRA) finerenone, represent agents capable of reducing metabolic, kidney and cardiovascular risk through complementary mechanisms of action. Current evidence supports use of these therapies in combination. Besides providing additive protective effects, combination therapy may also help reduce side effects. For instance, using an SGLT2 inhibitor in combination with finerenone helps decrease the risk for high potassium levels. Through the multipronged approach, combination therapy allows tailoring treatment for the individual patient characteristics and needs. Several planned and ongoing clinical trials continue to study the benefits of combination therapy in people with CKM syndrome. With building evidence supporting the use of combination therapy, it is crucial to raise awareness of the importance of this treatment approach and develop processes to incorporate new therapies into every day practice to support optimal care and improved outcomes. The global burden of chronic kidney disease (CKD) increased by nearly 90% in the period spanning 1990 to 2016, mostly attributed to an increase in the prevalence of CKD in diabetes. People living with CKD have an elevated lifetime risk for cardiovascular disease (CVD) when compared with the general population, with risk increasing in parallel with albuminuria and kidney function decline. Metabolic disease, CKD and CVD share common risk factors including neurohumoral activation, systemic inflammation and oxidative stress, thus prompting the introduction of a broader construct of cardiovascular–kidney–metabolic (CKM) syndrome. An important rationale for the introduction of this concept are recent and ongoing therapeutic advancements fundamentally changing CKM management. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and the non-steroidal mineralocorticoid receptor antagonist (ns-MRA) finerenone have shifted the therapeutic paradigm for patients with CKD and have emerged in rapid succession as cornerstones of guideline-directed medical therapy (GDMT). Recently completed clinical trials of aldosterone synthase inhibitors and endothelin receptor antagonists have additionally reported additive antiproteinuric effects on the background of renin–angiotensin system and SGLT2 inhibition, with acceptable safety profiles. The sum of current evidence from both preclinical and clinical studies support combination therapy in the setting of CKD to achieve additive and potentially synergistic kidney and heart protection by addressing metabolic, hemodynamic, and pro-inflammatory and pro-fibrotic mechanistic pathways. This narrative review will discuss available evidence supporting combination GDMT in CKD with diabetes and additionally discuss ongoing and future trials evaluating the efficacy and safety of combination therapies for CKD with or without diabetes.
- Open Access
- 29 December 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (1) , 201
Incretin Therapies for Patients with Type 2 Diabetes and Chronic Kidney Disease
Since the early 2000s, an influx of novel glucose-lowering agents has changed the therapeutic landscape for treatment of diabetes and diabetes-related complications. Glucagon-like peptide-1 (GLP-1) receptor agonists represent an important therapeutic class for the management of type 2 diabetes (T2D), demonstrating benefits beyond glycemic control, including lowering of blood pressure and body weight, and importantly, decreased risk of development of new or worsening chronic kidney disease (CKD) and reduced rates of atherosclerotic cardiovascular events. Plausible non-glycemic mechanisms that benefit the heart and kidneys with GLP-1 receptor agonists include anti-inflammatory and antioxidant effects. Further supporting their use in CKD, the glycemic benefits of GLP-1 receptor agonists are preserved in moderate-to-severe CKD. Considering current evidence, major guideline-forming organizations recommend the use of GLP-1 receptor agonists in cases of T2D and CKD, especially in those with obesity and/or in those with high cardiovascular risk or established heart disease. Evidence continues to build that supports benefits to the heart and kidneys of the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist tirzepatide. Ongoing outcome and mechanistic studies will continue to inform our understanding of the role of GLP-1 and dual GLP-1/GIP receptor agonists in diverse patient populations with kidney disease.
- 29 December 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (1) , 201
Open AccessIncretin Therapies for Patients with Type 2 Diabetes and Chronic Kidney Disease
Since the early 2000s, an influx of novel glucose-lowering agents has changed the therapeutic landscape for treatment of diabetes and diabetes-related complications. Glucagon-like peptide-1 (GLP-1) receptor agonists represent an important therapeutic class for the management of type 2 diabetes (T2D), demonstrating benefits beyond glycemic control, including lowering of blood pressure and body weight, and importantly, decreased risk of development of new or worsening chronic kidney disease (CKD) and reduced rates of atherosclerotic cardiovascular events. Plausible non-glycemic mechanisms that benefit the heart and kidneys with GLP-1 receptor agonists include anti-inflammatory and antioxidant effects. Further supporting their use in CKD, the glycemic benefits of GLP-1 receptor agonists are preserved in moderate-to-severe CKD. Considering current evidence, major guideline-forming organizations recommend the use of GLP-1 receptor agonists in cases of T2D and CKD, especially in those with obesity and/or in those with high cardiovascular risk or established heart disease. Evidence continues to build that supports benefits to the heart and kidneys of the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist tirzepatide. Ongoing outcome and mechanistic studies will continue to inform our understanding of the role of GLP-1 and dual GLP-1/GIP receptor agonists in diverse patient populations with kidney disease.
- Open Access
- 19 October 2023
- Published by MDPI AG in Diabetology
- Vol. 4 (4) , 453-464
Best Practices in the Use of Sodium–Glucose Cotransporter 2 Inhibitors in Diabetes and Chronic Kidney Disease for Primary Care
Diabetes is the leading cause of chronic kidney disease (CKD), with nearly half of all cases of kidney failure requiring kidney replacement therapy. While attention is often focused on the profound effects kidney failure has on the quality of life, the principal cause of complications and death among patients with diabetes and CKD is cardiovascular disease (CVD). These risks are often underappreciated by both healthcare professionals and patients. Sodium–glucose cotransporter 2 (SGLT-2) inhibitors were originally developed and approved as glucose-lowering agents for treating type 2 diabetes (T2D). However, agents within the SGLT-2 inhibitor class have since demonstrated robust benefits for CKD, atherosclerotic cardiovascular disease (ASCVD), and heart failure (HF) outcomes. Specifically, dedicated kidney disease and HF outcome trials have shown markedly reduced rates of kidney failure, CVD and HF events, and death among people (with and without diabetes) with CKD. SGLT-2 inhibitors will be used by primary care clinicians, nephrologists, and cardiologists across a range of cardiovascular and kidney conditions and diabetes. Knowledge and awareness of the benefits and key safety considerations, and risk mitigation strategies for these medications is imperative for clinicians to optimize the use of these life-saving therapies.
- 19 October 2023
- Published by MDPI AG in Diabetology
- Vol. 4 (4) , 453-464
Open AccessBest Practices in the Use of Sodium–Glucose Cotransporter 2 Inhibitors in Diabetes and Chronic Kidney Disease for Primary Care
Diabetes is the leading cause of chronic kidney disease (CKD), with nearly half of all cases of kidney failure requiring kidney replacement therapy. While attention is often focused on the profound effects kidney failure has on the quality of life, the principal cause of complications and death among patients with diabetes and CKD is cardiovascular disease (CVD). These risks are often underappreciated by both healthcare professionals and patients. Sodium–glucose cotransporter 2 (SGLT-2) inhibitors were originally developed and approved as glucose-lowering agents for treating type 2 diabetes (T2D). However, agents within the SGLT-2 inhibitor class have since demonstrated robust benefits for CKD, atherosclerotic cardiovascular disease (ASCVD), and heart failure (HF) outcomes. Specifically, dedicated kidney disease and HF outcome trials have shown markedly reduced rates of kidney failure, CVD and HF events, and death among people (with and without diabetes) with CKD. SGLT-2 inhibitors will be used by primary care clinicians, nephrologists, and cardiologists across a range of cardiovascular and kidney conditions and diabetes. Knowledge and awareness of the benefits and key safety considerations, and risk mitigation strategies for these medications is imperative for clinicians to optimize the use of these life-saving therapies.